학술논문

Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial
Document Type
Journal
Source
ANNALS OF ONCOLOGY; OCT 2019, 30 p634-p+, 2p. Supplement: 5
Subject
Language
English
ISSN
15698041